Cargando…

Targeting PGM3 as a Novel Therapeutic Strategy in KRAS/LKB1 Co-Mutant Lung Cancer

In non-small-cell lung cancer (NSCLC), concurrent mutations in the oncogene KRAS and tumor suppressor STK11 (also known as LKB1) confer an aggressive malignant phenotype, an unfavourability towards immunotherapy, and overall poor prognoses in patients. In a previous study, we showed that murine KRAS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Hyunmin, Cai, Feng, Kelekar, Neil, Velupally, Nipun K., Kim, Jiyeon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750012/ https://www.ncbi.nlm.nih.gov/pubmed/35011738 http://dx.doi.org/10.3390/cells11010176

Ejemplares similares

The hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1-mutant lung cancer
por: Kim, Jiyeon, et al.
Publicado: (2020)

CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells
por: Kim, Jiyeon, et al.
Publicado: (2017)

Phenformin enhances the therapeutic effect of selumetinib in KRAS-mutant non-small cell lung cancer irrespective of LKB1 status
por: Zhang, Jun, et al.
Publicado: (2017)

KRAS/LKB1 and KRAS/TP53 co-mutations create divergent immune signatures in lung adenocarcinomas
por: Gu, Meichen, et al.
Publicado: (2021)

Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies
por: Désage, Anne-Laure, et al.
Publicado: (2022)

An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer
por: Wang, Haiyun, et al.
Publicado: (2019)

Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC
por: Liu, Weiran, et al.
Publicado: (2016)

Mild Oxidative Stress Reduces NRF2 SUMOylation to Promote Kras/Lkb1/Keap1 Mutant Lung Adenocarcinoma Cell Migration and Invasion
por: Xu, Jiaqian, et al.
Publicado: (2020)

KRAS mutant lung cancer: progress thus far on an elusive therapeutic target
por: Bhattacharya, Saveri, et al.
Publicado: (2015)

A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
por: Pang, Xiufeng, et al.
Publicado: (2016)

LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition
por: Mahoney, C L, et al.
Publicado: (2009)

KRAS-Mutant Lung Cancer: Targeting Molecular and Immunologic Pathways, Therapeutic Advantages and Restrictions
por: Karimi, Nastaran, et al.
Publicado: (2023)

A combinatorial strategy for treating KRAS mutant lung cancer
por: Manchado, Eusebio, et al.
Publicado: (2016)

Glucocorticoid mediated inhibition of LKB1 mutant non-small cell lung cancers
por: Huffman, Kenneth E., et al.
Publicado: (2023)

Inhibition of autophagy and MEK promotes ferroptosis in Lkb1-deficient Kras-driven lung tumors
por: Bhatt, Vrushank, et al.
Publicado: (2023)

Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas
por: Baldelli, Elisa, et al.
Publicado: (2021)

Targeting the Tumor Microenvironment: An Unexplored Strategy for Mutant KRAS Tumors
por: Dias Carvalho, Patrícia, et al.
Publicado: (2019)

TUSC2 immunogene enhances efficacy of chemo-immuno combination on KRAS/LKB1 mutant NSCLC in humanized mouse model
por: Meraz, Ismail M., et al.
Publicado: (2022)

Targeting KRAS in Cancer: Promising Therapeutic Strategies
por: Mustachio, Lisa Maria, et al.
Publicado: (2021)

Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies
por: Cucurull, Marc, et al.
Publicado: (2022)

Targeting KRAS mutant lung cancer: light at the end of the tunnel
por: Drosten, Matthias, et al.
Publicado: (2022)

Expression profiling of ubiquitin-related genes in LKB1 mutant lung adenocarcinoma
por: Wang, Guanghui, et al.
Publicado: (2018)

Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors
por: Baldelli, Elisa, et al.
Publicado: (2015)

Autophagy modulates lipid metabolism to maintain metabolic flexibility for Lkb1-deficient Kras-driven lung tumorigenesis
por: Bhatt, Vrushank, et al.
Publicado: (2019)

G6PD Maintains Redox Homeostasis and Biosynthesis in LKB1-Deficient KRAS-Driven Lung Cancer
por: Lan, Taijin, et al.
Publicado: (2023)

Snail acetylation by autophagy‐derived acetyl‐coenzyme A promotes invasion and metastasis of KRAS‐LKB1 co‐mutated lung cancer cells
por: Han, Jang Hee, et al.
Publicado: (2022)

A subset of VEGFR‐TKIs activates AMPK in LKB1‐mutant lung cancer
por: Yang, Lujie, et al.
Publicado: (2022)

The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer
por: Diehl, J. Nathaniel, et al.
Publicado: (2021)

Targeting CDK4 overcomes EMT-mediated tumor heterogeneity and therapeutic resistance in KRAS-mutant lung cancer
por: Padhye, Aparna, et al.
Publicado: (2021)

Current therapy of KRAS-mutant lung cancer
por: Ghimessy, Aron, et al.
Publicado: (2020)

LKB1 tumor suppressor: Therapeutic opportunities knock when LKB1 is inactivated
por: Zhou, Wei, et al.
Publicado: (2014)

Integrative analysis reveals distinct subtypes with therapeutic implications in KRAS-mutant lung adenocarcinoma
por: Liu, Ke, et al.
Publicado: (2018)

A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS
por: Bery, Nicolas, et al.
Publicado: (2020)

Effectors and potential targets selectively upregulated in human KRAS-mutant lung adenocarcinomas
por: Li, Jinyu, et al.
Publicado: (2016)

The Prognostic Model and Drug Sensitivity of LKB1-Mutant Lung Adenocarcinoma Based on Immune Landscape
por: Wang, Guanghui, et al.
Publicado: (2022)

Acquired palbociclib resistance in KRAS-mutant lung cancer
por: Sherr, Charles J.
Publicado: (2018)

Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future
por: Uras, Iris Z., et al.
Publicado: (2020)

Targeting ST2 expressing activated regulatory T cells in Kras-mutant lung cancer
por: Kim, Byung-Seok, et al.
Publicado: (2019)

The level of oncogenic Ras determines the malignant transformation of Lkb1 mutant tissue in vivo
por: Rackley, Briana, et al.
Publicado: (2021)

Targeting Mutant KRAS in Pancreatic Cancer: Futile or Promising?
por: Nollmann, Friederike Inga, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_o0o8ipe3smjuas629pscalsh7h